Untreated Mantle Cell Lymphoma Clinical Trial
Official title:
Phase II Study of Bevacizumab Plus CHOP-Rituximab in Patients With Untreated Mantle Cell Lymphoma (NHL)
Primary Objective
1. To evaluate the safety profile of Bevacizumab (Bevacizumab™)- Rituximab (Rituxan®)-CHOP
(RA-CHOP) in patients with newly diagnosed mantle cell lymphoma (MCL).
Secondary Objectives
1. To evaluate the response rate and time to disease progression of the RA-CHOP regimen in
patients with newly diagnosed MCL.
2. To prospectively characterize the angiogenic profiles of MCL patients during RA-CHOP
treatment.
Bevacizumab administered at 15 mg/kg on day 1 of each of 6 cycles
Rituximab administered 375 mg/m2 on day 3 of each of 6 cycles (with usual premedications)
Standard CHOP chemotherapy administered on day 3 every 21 days (full dose) for 6 cycles of
treatment
Once completed six cycles of therapy (~18 weeks), patients will be evaluated every 3 months
for the first year post treatment, then every 6 months until disease progression or death for
years 2 through 5 post treatment. Patients who have disease progression will be contacted
every 6 months until death to assess for survival status.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05504603 -
Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma
|
Phase 2 |